表紙
市場調査レポート

MediPoint:薬剤溶出バルーン市場 - 米国市場の分析と予測

MediPoint: Drug-Eluting Balloons - US Analysis and Market Forecasts

発行 GlobalData 商品コード 288617
出版日 ページ情報 英文 377 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
MediPoint:薬剤溶出バルーン市場 - 米国市場の分析と予測 MediPoint: Drug-Eluting Balloons - US Analysis and Market Forecasts
出版日: 2013年09月30日 ページ情報: 英文 377 Pages
概要

当レポートでは、米国における薬剤溶出バルーン(DEB)市場について分析し、疾患(冠動脈/末梢動脈疾患)の概要や産業構造、全体的な市場動向(過去3年間の実績値と今後7年間の予測値)、現在・将来の競争状況、主な市場促進・抑制要因、アンメットニーズ、治験中/上市済みの主要製品の情報、現在活動中または今後参入予定の主要企業の概要(プロファイル・製品構成・SWOT分析)、米国市場の詳細動向などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 概要(冠動脈疾患・末梢動脈疾患)
  • 生体構造・生理機能
  • 病態
  • 臨床症状
    • 兆候
    • リスク要因
    • 疾患の分類
    • 診断
    • 臨床転帰
  • 疫学
  • 経済的影響:冠動脈/末梢動脈疾患の治療費

第4章 競争分析

  • 概要
  • 各企業の製品プロファイル(計12社分)

第5章 アンメットニーズ

  • 特異性障害に対する臨床転帰の改善の必要性
  • 大腿膝窩動脈再生の改善の必要性
  • 膝窩動脈下動脈の治療の難しさ
  • バルーン血管形成術の失敗メカニズムの除去
  • 末梢血管ステントに関する課題への対処
  • 一部の患者層への効果的な治療法の必要性
  • 臨床データの欠如
  • 下肢バイパス手術の複雑性への対処
  • 医薬療法の改善の必要性
  • 末梢動脈疾患(PAD)向け運動療法の比較研究

第6章 パイプライン製品

  • 概要
  • 開発段階別のパイプライン
  • パイプライン製品のプロファイル(全15種類)

第7章 治験の分析

  • 概要
  • 注目すべき治験(薬剤溶出バルーン、血管ステント)

第8章 産業の概要

  • 治療法の傾向
    • 冠動脈・末梢動脈のインターベンションの促進要因
    • 冠動脈/末梢動脈疾患
  • 医師側の意志決定過程
  • 市場アクセス
    • 規制過程
    • 導入
    • 米国国内の医療費償還傾向
  • 規制上の課題とリコール
  • 企業合併・買収(M&A)/パートナーシップの動向
    • 製品リコール
  • 企業合併・買収(M&A)/パートナーシップの動向(全7件)

第9章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル(全24社分)
    • Aachen Resonance
    • AnGes MG
    • AngioScore
    • AVIDAL Vascular
    • B. Braun
    • Biosensors International
    • Biotronik
    • Blue Medical
    • Boston Scientific Corporation
    • Caliber Therapeutics
    • Cardionovum
    • Concept Medical Research
    • Cook Medical
    • Covidien
    • C.R. Bard
    • DSM Biomedical
    • Elixir Medical Corporation
    • Eurocor
    • LifeTech Scientific Corporation
    • Medtronic
    • Micell Technologies
    • Minvasys
    • TriReme Medical
    • Vascular Nanotransfer Technologies

第10章 市場の促進要因・機会・障壁・代替製品

  • 市場促進要因
    • 疾患の有病率の上昇
    • 特定の疾患向けの実現可能な治療法
    • 金属残存の回避
    • 「ステント・イン・ステント」処置の回避
    • 二重抗血小板療法の必要性の軽減
    • 血管治療の促進と開存性の改善
    • 将来のインターベンションの技術的可能性
    • 補助療法としての薬剤溶出バルーン
    • 手足の切断
    • コスト抑制
    • 長期的データの入手可能性
    • 米国での血管ステント製品の発売予定
  • 市場機会
    • 薬剤溶出バルーン(DEB)の設計の改善
    • DEBハイブリッドシステム(薬剤溶出バルーン+ステント)
    • ステントでは十分に対処できない疾患の治療法
    • 大腿膝窩動脈・膝窩動脈下動脈の治療に関する課題
    • 高リスク患者を対象とした製品
    • 日本市場での血管ステント製品の発売
    • 新興国市場
  • 市場の障壁
    • 導入の遅さ
    • 販売価格の高さ
    • 医療費償還制度の不足
    • 米国FDA(食品医薬品局)の規制に関する課題
    • 医療費支出の削減と医療費償還
    • ベンチャーキャピタルの利用可能性
    • 医療機器に対する物品税
  • 代替製品
    • 血管ステント
    • 液体薬剤送達用カテーテル

第11章 薬剤溶出バルーン市場の分析

  • 市場の分布:適応症別
  • 一次/補助療法
  • 比較市場分析
    • 冠動脈疾患
    • 下肢末梢動脈疾患

第12章 国の見通しと予測

  • 米国
    • 概要
    • 市場分析

第13章 付録

図表一覧

目次
Product Code: GDME1057CFR

GlobalData has released its medical devices report, "MediPoint: Drug-Eluting Balloons - US Analysis and Market Forecasts". The report is an essential source of information and analysis on the drug-eluting balloons (DEB) market in the US. The report provides in-depth insight into the use of DEB for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics.

The DEB market in the US was assessed to identify the unmet needs in the market, understand the regulatory challenges DEB manufacturers will encounter in the US, identify the challenges to adoption in clinical practice and evaluate future adoption of DEB for select coronary and peripheral indications. The US sales expectations are discussed through careful analysis of adoption patterns of using DEB.

Clients can use this report to better understand the scope of this technology and for strategic planning to explore opportunities in this dynamic market. The report provides insights into the competitive landscape, the marketed and pipeline DEB products, the current and emerging players and comparative market analysis of different types of interventional techniques used to treat coronary and peripheral artery disease. This report is built using data and information sourced from secondary sources and primary research interviews and survey with leading Interventional Cardiologists and Interventional Radiologists, with in-house analysis conducted by GlobalData's team of industry experts.

Scope

  • An overview of coronary artery disease and peripheral artery disease in the lower extremity, which includes epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
  • Annualized total drug-eluting balloon market revenue by type of disease, annual cost of disease and drug-eluting balloons adoption pattern and procedure data in the US from 2010-2012 and forecast for seven years to 2019.
  • Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access and implications of the drug-eluting balloon market.
  • Pipeline analysis: comprehensive data split across different stages of development, emerging trends and DEB designs in development, including investigation of DEB coating technology, antiproliferative agent used, balloon and catheter design and durability.
  • Analysis of the current and future market competition in the US drug-eluting balloon market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends that will shape and drive the DEB market in the US.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US DEB market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the US DEB market by disease and indication from 2010-2019.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Disease Overview

  • 3.1. Overview
    • 3.1.1. Coronary Artery Disease
    • 3.1.2. Peripheral Artery Disease
  • 3.2. Anatomy and Physiology
    • 3.2.1. Coronary Arteries
    • 3.2.2. Peripheral Arteries of the Lower Extremity
  • 3.3. Pathophysiology
    • 3.3.1. Coronary Artery Disease
    • 3.3.2. Peripheral Artery Disease
  • 3.4. Clinical Presentation
    • 3.4.1. Symptoms
    • 3.4.2. Risk Factors
    • 3.4.3. Disease Classification
    • 3.4.4. Diagnosis
    • 3.4.5. Clinical Outcomes
  • 3.5. Epidemiology
    • 3.5.1. Coronary Artery Disease
    • 3.5.2. Peripheral Artery Disease
  • 3.6. Economic Impact of Coronary and Peripheral Artery Disease
    • 3.6.1. Cost of Coronary Artery Disease
    • 3.6.2. Cost of Peripheral Artery Disease
    • 3.6.3. Treatment Costs of Coronary and Peripheral Artery Disease

4. Competitive Assessment

  • 4.1. Overview
  • 4.2. Product Profiles by Company
    • 4.2.1. Aachen Resonance
    • 4.2.2. B. Braun
    • 4.2.3. Biotronik
    • 4.2.4. Blue Medical
    • 4.2.5. Cardionovum
    • 4.2.6. C.R. Bard
    • 4.2.7. Concept Medical Research
    • 4.2.8. Cook Medical
    • 4.2.9. Eurocor
    • 4.2.10. Medrad (Bayer Healthcare)
    • 4.2.11. Medtronic
    • 4.2.12. Minvasys

5. Unmet Needs

  • 5.1. Need for Better Clinical Outcomes in Specific Lesions
    • 5.1.1. Chronic Total Occlusions
    • 5.1.2. Small-Vessel Coronary Lesions
    • 5.1.3. Long Lesions
    • 5.1.4. Heavily-Calcified and Uncrossable/Undilatable Lesions
    • 5.1.5. Bifurcation Lesions
  • 5.2. Need for Better Revascularization of the Femoropopliteal Artery
  • 5.3. Difficulty in Treating the Infrapopliteal Artery
  • 5.4. Eliminating Mechanisms of Failure with Balloon Angioplasty
  • 5.5. Addressing Challenges of Stenting
    • 5.5.1. Risk of Post-Procedural Complications
    • 5.5.2. In-Stent Restenosis
    • 5.5.3. Stent-In-Stent Procedures
    • 5.5.4. Prolonged Dual Antiplatelet Therapy
    • 5.5.5. Lack of Homogenous Drug Distribution
    • 5.5.6. Delayed Healing
    • 5.5.7. Stent Fracture
    • 5.5.8. Negative Vessel Remodeling
    • 5.5.9. Long-Term Vessel Patency
  • 5.6. Need for Effective Therapy for Specific Patient Populations
  • 5.7. Lack of Clinical Data
  • 5.8. Addressing the Complications of Bypass Surgery
  • 5.9. Need to Improve Medical Therapy
  • 5.10. Comparative Studies on Exercise Therapy for PAD

6. Pipeline Products

  • 6.1. Overview
  • 6.2. Pipeline by Stage of Development
  • 6.3. Pipeline Product Profiles
    • 6.3.1. NF-KB Decoy Oligo DEB
    • 6.3.2. Drug-Coated AngioSculpt
    • 6.3.3. BioPath
    • 6.3.4. BioStream
    • 6.3.5. Boston Scientific Drug-Coated Balloon
    • 6.3.6. Coroflex DEBlue
    • 6.3.7. Covidien Drug-Coated Balloon
    • 6.3.8. Caliber Therapeutics DEB
    • 6.3.9. Elixir Medical Corporation DCB
    • 6.3.10. LifeTech Scientific Corporation DEB
    • 6.3.11. Micell Technologies Drug-Coated Balloon
    • 6.3.12. Drug-Coated Chocolate DEB
    • 6.3.13. Passeo-18 Lux
    • 6.3.14. Vascular Nanotransfer Technologies Drug-Coated Balloon
    • 6.3.15. WOMBAT DCB

7. Clinical Trial Analysis

  • 7.1. Overview
  • 7.2. Clinical Trials to Watch
    • 7.2.1. Drug-Eluting Balloons
    • 7.2.2. Vascular Stents

8. Industry Overview

  • 8.1. Procedure Trends
    • 8.1.1. Factors Contributing to the Rise of Coronary and Peripheral Interventions
    • 8.1.2. Coronary Artery Disease
    • 8.1.3. Peripheral Artery Disease
  • 8.2. Physician Decision-Making Process
  • 8.3. Market Access
    • 8.3.1. Regulatory Process
    • 8.3.2. Adoption
    • 8.3.3. Reimbursement Trends in US
  • 8.4. Regulatory Issues/Recalls
    • 8.4.1. Product Recalls
  • 8.5. Mergers and Acquisitions/Partnerships
    • 8.5.1. Biosensors International and Eurocor
    • 8.5.2. Boston Scientific Corporation and Guidant Corporation
    • 8.5.3. Covidien and ev3, CV Ingenuity
    • 8.5.4. C.R. Bard and Lutonix
    • 8.5.5. Micell Technologies and Maxcor Lifescience
    • 8.5.6. Medrad and Bayer
    • 8.5.7. Medtronic and Invatec

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Aachen Resonance
    • 9.3.2. AnGes MG
    • 9.3.3. AngioScore
    • 9.3.4. AVIDAL Vascular
    • 9.3.5. B. Braun
    • 9.3.6. Biosensors International
    • 9.3.7. Biotronik
    • 9.3.8. Blue Medical
    • 9.3.9. Boston Scientific Corporation
    • 9.3.10. Caliber Therapeutics
    • 9.3.11. Cardionovum
    • 9.3.12. Concept Medical Research
    • 9.3.13. Cook Medical
    • 9.3.14. Covidien
    • 9.3.15. C.R. Bard
    • 9.3.16. DSM Biomedical
    • 9.3.17. Elixir Medical Corporation
    • 9.3.18. Eurocor
    • 9.3.19. LifeTech Scientific Corporation
    • 9.3.20. Medtronic
    • 9.3.21. Micell Technologies
    • 9.3.22. Minvasys
    • 9.3.23. TriReme Medical
    • 9.3.24. Vascular Nanotransfer Technologies

10. Market Drivers, Opportunities, Barriers and Substitutes

  • 10.1. Market Drivers
    • 10.1.1. Rising Prevalence of Disease
    • 10.1.2. Viable Treatment for Select Indications
    • 10.1.3. No Metal Left Behind
    • 10.1.4. Avoid Stent-in-Stent Procedures
    • 10.1.5. Reduce the Need for Prolonged Dual Antiplatelet Therapy
    • 10.1.6. Enhanced Vessel Healing and Better Patency
    • 10.1.7. Technical Feasibility of Future Interventions
    • 10.1.8. DEB as an Adjunctive Therapy
    • 10.1.9. Limb Amputation
    • 10.1.10. Cost Savings
    • 10.1.11. Availability of Long-Term and Cost-Effective Data
    • 10.1.12. Launch of DEB in the US
  • 10.2. Opportunities
    • 10.2.1. Improve DEB Design
    • 10.2.2. DEB Hybrid Systems (DEB + Stent)
    • 10.2.3. Target Indications Where Stenting is Not Satisfactory
    • 10.2.4. Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries
    • 10.2.5. Target Challenging Patient Populations
    • 10.2.6. Launch DEB in the Japanese Market
    • 10.2.7. Emerging Markets
  • 10.3. Market Barriers
    • 10.3.1. Slow Adoption
    • 10.3.2. High Selling Prices
    • 10.3.3. Lack of Reimbursement
    • 10.3.4. US FDA Regulatory Challenges
    • 10.3.5. Healthcare Cost-Cutting and Reimbursement
    • 10.3.6. Availability of Venture Capital
    • 10.3.7. Medical Device Excise Tax
  • 10.4. Market Substitutes
    • 10.4.1. Vascular Stents
    • 10.4.2. Liquid Drug Delivery Catheter

11. Drug-Eluting Balloon Market Analysis

  • 11.1. Market Distribution by Indication
  • 11.2. Primary Versus Adjunctive Therapy
  • 11.3. Comparative Market Analysis
    • 11.3.1. Coronary Artery Disease
    • 11.3.2. Peripheral Artery Disease in the Lower Extremity

12. Country Outlooks & Forecasts

  • 12.1. United States
    • 12.1.1. Overview
    • 12.1.2. Market Analysis

13. Appendix

  • 13.1. Bibliography
  • 13.2. Abbreviations
  • 13.3. Report Methodology
    • 13.3.1. Overview
    • 13.3.2. Coverage
    • 13.3.3. Secondary Research
    • 13.3.4. Forecasting Methodology
  • 13.4. Physicians and Specialists Included in this Study
  • 13.5. Physician Survey
  • 13.6. About the Authors
    • 13.6.1. Analysts
    • 13.6.2. Global Head of Healthcare
  • 13.7. About MediPoint
  • 13.8. About GlobalData
  • 13.9. Disclaimer

List of Tables

  • Table 1: Classification Systems for Determining the Severity of PAD Symptoms
  • Table 2: Risk Factors Associated with CAD and PAD
  • Table 3: Types of Atherosclerotic Lesions
  • Table 4: Treatment Guidelines to Improve the Symptoms of CAD*
  • Table 5: TASC II Classification of Iliac Artery Lesions
  • Table 6: TASC II Classification of Femoropopliteal Artery Lesions
  • Table 7: TASC II Classification of Infrapopliteal Artery Lesions
  • Table 8: Types of Coronary Artery Bypass Grafting
  • Table 9: Complications of Coronary/Peripheral Artery Bypass Surgery
  • Table 10: Indications for Using Drug-Eluting Balloons
  • Table 11: Drug-Eluting Balloon Coating Characteristics
  • Table 12: Drugs Incorporated Into Drug-Eluting Stents
  • Table 13: Types of Lesions Treated Using Atherectomy
  • Table 14: Prevalence of CAD in the Population Age ≥65 Years in the US (millions), 2010-2019
  • Table 15: Prevalence of PAD in the Population Age ≥65 Years in the US (millions), 2010-2019
  • Table 16: Direct and Indirect Healthcare Costs
  • Table 17: Healthcare Expenditures ($bn, 2008$) for CAD in the US
  • Table 18: Healthcare Expenditures ($bn) for PAD in the US
  • Table 19: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2010-2019 ($US)
  • Table 20: Marketed DEB Products
  • Table 21: Elutax SV Product Portfolio
  • Table 22: Elutax SV SWOT Analysis, 2013
  • Table 23: SeQuent Please Product Portfolio
  • Table 24: SeQuent Please SWOT Analysis, 2013
  • Table 25: Pantera Lux Product Portfolio
  • Table 26: Pantera Lux SWOT Analysis, 2013
  • Table 27: Pioneer Product Portfolio
  • Table 28: Pioneer SWOT Analysis, 2013
  • Table 29: Protege Product Portfolio
  • Table 30: Protege SWOT Analysis, 2013
  • Table 31: Restore DEB Product Portfolio
  • Table 32: Restore DEB SWOT Analysis, 2013
  • Table 33: Legflow DEB Product Portfolio
  • Table 34: Legflow DEB SWOT Analysis, 2013
  • Table 35: Other DEB Products Developed by Cardionovum
  • Table 36: Lutonix Product Portfolio
  • Table 37: Lutonix SWOT Analysis, 2013
  • Table 38: Magic Touch Product Portfolio
  • Table 39: Magic Touch SWOT Analysis, 2013
  • Table 40: Advance 18 PTX Product Portfolio
  • Table 41: Advance 18 PTX SWOT Analysis, 2013
  • Table 42: Dior Product Portfolio
  • Table 43: Dior SWOT Analysis, 2013
  • Table 44: Freeway Family of DEB Product Portfolio
  • Table 45: Freeway Family of DEB SWOT Analysis, 2013
  • Table 46: Magical Product Portfolio
  • Table 47: Magical SWOT Analysis, 2013
  • Table 48: Cotavance Product Portfolio
  • Table 49: Cotavance SWOT Analysis, 2013
  • Table 50: IN.PACT Family DEB Product Portfolio
  • Table 51: IN.PACT SWOT Analysis, 2013
  • Table 52: Danubio Product Portfolio
  • Table 53: Danubio SWOT Analysis, 2013
  • Table 54: Global DEB Pipeline Products
  • Table 55: NF-KB Decoy Oligo DEB SWOT Analysis, 2013
  • Table 56: AngioSculpt SWOT Analysis, 2013
  • Table 57: BioPath SWOT Analysis, 2013
  • Table 58: BioStream SWOT Analysis, 2013
  • Table 59: Boston Scientific DEB SWOT Analysis, 2013
  • Table 60: Coroflex DEBlue SWOT Analysis, 2013
  • Table 61: Covidien DCB SWOT Analysis, 2013
  • Table 62: Micell Technologies' DCB SWOT Analysis, 2013
  • Table 63: Drug-Coated Chocolate DEB SWOT Analysis, 2013
  • Table 64: Passeo-18 Lux SWOT Analysis, 2013
  • Table 65: Vascular Nanotransfer Technologies DCB SWOT Analysis, 2013
  • Table 66: WOMBAT DCB SWOT Analysis, 2013
  • Table 67: Medicare National Average of Inpatient Hospital Payment for Coronary and Peripheral Interventions, 2012-2013
  • Table 68: Aachen Resonance Company Profile
  • Table 69: Aachen Resonance, Marketed DEB Product
  • Table 70: Aachen Resonance SWOT Analysis, 2013
  • Table 71: AnGes MG Company Profile
  • Table 72: AnGes MG, Pipeline DEB Product
  • Table 73: AnGes MG SWOT Analysis, 2013
  • Table 74: AngioScore Company Profile
  • Table 75: AngioScore, Pipeline DEB Product
  • Table 76: AngioScore SWOT Analysis, 2013
  • Table 77: AVIDAL Vascular Company Profile
  • Table 78: AVIDAL Vascular, Pipeline DEB Product
  • Table 79: AVIDAL Vascular SWOT Analysis, 2013
  • Table 80: B. Braun Company Profile
  • Table 81: B. Braun, Marketed and Pipeline DEB Products
  • Table 82: B. Braun SWOT Analysis, 2013
  • Table 83: Biosensors International Company Profile
  • Table 84: Biosensors International, Pipeline DEB Products
  • Table 85: Biosensors International SWOT Analysis, 2013
  • Table 86: Biotronik Company Profile
  • Table 87: Biotronik, Marketed and Pipeline DEB Products
  • Table 88: Biotronik SWOT Analysis, 2013
  • Table 89: Blue Medical Company Profile
  • Table 90: Blue Medical, Marketed DEB Products
  • Table 91: Blue Medical SWOT Analysis, 2013
  • Table 92: Boston Scientific Corporation Company Profile
  • Table 93: Boston Scientific Corporation, Pipeline DEB Product
  • Table 94: Boston Scientific Corporation SWOT Analysis, 2013
  • Table 95: Caliber Therapeutics Company Profile
  • Table 96: Caliber Therapeutics, Pipeline DEB Product
  • Table 97: Caliber Therapeutics SWOT Analysis, 2013
  • Table 98: Cardionovum Company Profile
  • Table 99: Cardionovum, Marketed and Pipeline DEB Products
  • Table 100: Cardionovum SWOT Analysis, 2013
  • Table 101: Concept Medical Research Company Profile
  • Table 102: Concept Medical Research, Marketed DEB Product
  • Table 103: Concept Medical Research SWOT Analysis, 2013
  • Table 104: Cook Medical Company Profile
  • Table 105: Cook Medical, Marketed DEB Product
  • Table 106: Cook Medical SWOT Analysis, 2013
  • Table 107: Covidien Company Profile
  • Table 108: Covidien, Pipeline DEB Product
  • Table 109: Covidien SWOT Analysis, 2013
  • Table 110: C.R. Bard Company Profile
  • Table 111: C.R. Bard, Marketed DEB Products
  • Table 112: C.R. Bard SWOT Analysis, 2013
  • Table 113: DSM Biomedical Company Profile
  • Table 114: DSM Biomedical, Pipeline DEB Product
  • Table 115: DSM Biomedical SWOT Analysis, 2013
  • Table 116: Elixir Medical Corporation Company Profile
  • Table 117: Elixir Medical Corporation, Pipeline DEB Product
  • Table 118: Elixir Medical Corporation SWOT Analysis, 2013
  • Table 119: Eurocor Company Profile
  • Table 120: Eurocor, Marketed DEB Products
  • Table 121: Eurocor SWOT Analysis, 2013
  • Table 122: LifeTech Scientific Corporation Company Profile
  • Table 123: LifeTech Scientific, Pipeline DEB Product
  • Table 124: LifeTech Scientific SWOT Analysis, 2013
  • Table 125: Medtronic Company Profile
  • Table 126: Medtronic, Marketed DEB Products
  • Table 127: Medtronic SWOT Analysis, 2013
  • Table 128: Micell Technologies Company Profile
  • Table 129: Micell Technologies, Pipeline DEB Product
  • Table 130: Micell Technologies SWOT Analysis, 2013
  • Table 131: Minvasys Company Profile
  • Table 132: Minvasys, Marketed DEB Product
  • Table 133: Minvasys SWOT Analysis, 2013
  • Table 134: TriReme Medical Company Profile
  • Table 135: TriReme Medical, Pipeline DEB Product
  • Table 136: TriReme Medical SWOT Analysis, 2013
  • Table 137: Vascular Nanotransfer Technologies Company Profile
  • Table 138: Vascular Nanotransfer Technologies, Pipeline DEB Product
  • Table 139: Vascular Nanotransfer Technologies SWOT Analysis, 2013
  • Table 140: Percent of Patients with CAD or PAD Expected to Receive Stenting with DEB Angioplasty, US, 2018 (N=12)
  • Table 141: DEB Sales ($m) Forecast for the United States, 2010-2019
  • Table 142: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Coronary Arteries of the Human Heart
  • Figure 2: Peripheral Arteries of the Lower Extremity
  • Figure 3: Pathophysiology of Coronary Artery Disease
  • Figure 4: Pathophysiology of Peripheral Artery Disease
  • Figure 5: Treatment Modalities - Coronary Artery Disease
  • Figure 6: Percent of Patients with CAD Who Receive Each Therapy Option Only, US, 2012 and 2019 (N=5)
  • Figure 7: Treatment Modalities - Peripheral Artery Disease
  • Figure 8: Percent of Patients with PAD Who Receive Each Therapy Option Only, US, 2012 (N=7)
  • Figure 9: Percent of Patients with PAD Who Receive Each Therapy Option Only, US, 2012 (N=7)
  • Figure 10: Drug-Eluting Balloon
  • Figure 11: Types of Stents Used to Treat CAD and PAD
  • Figure 12: Bare Metal Stent
  • Figure 13: Drug-Eluting Stent
  • Figure 14: Covered Stents
  • Figure 15: Bioabsorbable Stent - Remedy
  • Figure 16: Types of Atherectomy
  • Figure 17: Prevalence of CAD in the Population Age ≥65 Years in the US (millions), 2010-2019
  • Figure 18: Prevalence of PAD in the Population Age ≥65 Years in the US (millions), 2010-2019
  • Figure 19: Healthcare Expenditures ($bn, 2008$) for CAD in the US
  • Figure 20: Healthcare Expenditures ($bn) for PAD in the US
  • Figure 21: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2010-2019 ($US)
  • Figure 22: Image of the Protege DEB
  • Figure 23: Percent of CAD and PAD Patients with Acute Vessel Recoil After Standard Balloon Angioplasty, US, 2012 and 2018 (N=12)
  • Figure 24: Percent of CAD and PAD Patients with Thrombosis After Stenting, US, 2012 and 2018 (N=12)
  • Figure 25: Percent of CAD and PAD Patients with ISR, US, 2012 and 2018 (N=12)
  • Figure 26: Percent of CAD and PAD Patients Who Receive Stent-In-Stent Procedures, US, 2012 and 2018 (N=12)
  • Figure 27: Percent of CAD and PAD Patients with Stent Fracture, US, 2012 and 2018 (N=12)
  • Figure 28: Global DEB Pipeline Products by Stage of Development, 2013
  • Figure 29: AngioSculpt Scoring Balloon Expansion Profile
  • Figure 30: Drug-Coated Chocolate DEB
  • Figure 31: Population (≥ 65 years) of CAD Patients Receiving Interventional Procedures, US, 2010-2019
  • Figure 32: Population (≥ 65 years) of PAD Patients Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, US, 2010-2019
  • Figure 33: Population (≥ 65 years) of PAD Patients Receiving DEB Angioplasty for the Peripheral Arteries in the Lower Extremity, US, 2010-2019
  • Figure 34: Medicare National Average of Outpatient Hospitalization Payment for PCI and Endovascular Procedures, 2012-2013
  • Figure 35: DEB Market for Treating CAD and PAD in the Lower Extremity, Company Share (%), 2012
  • Figure 36: DEB Market for Each Type of Disease, Company Share (%), 2012
  • Figure 37: Importance of Each Therapy Attribute in Adopting DEB for the Treatment of CAD and PAD, Global, 2012 (N=112)
  • Figure 38: Projected US DEB Market Distribution (%) by Indication, 2018 (N=12)
  • Figure 39: Percent of Patients with CAD Receiving Each Type of Interventional Technique Only, US, 2018 (N=5)
  • Figure 40: Percent of Patients with Lower Limb PAD Receiving Each Type of Interventional Technique Only, US, 2018 (N=7)
  • Figure 41: US DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019
Back to Top